Clinical Trial Update: A Study to Determine Effective and Tolerable Titration Scheme for OROS-Methylphenidate in Children With Attention-deficit Hyperactivity Disorder [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluated effective and tolerable titration schemes for OROS-Methylphenidate in children with Attention-Deficit/Hyperactivity Disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• OROS-Methylphenidate (methylphenidate, osmotic release formulation)

Snippet

Sponsor: Johnson & Johnson Taiwan Ltd | Conditions: Attention Deficit Hyperactivity Disorder | Phase 4 | Status: COMPLETED